Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Head Neck ; 38(5): 775-81, 2016 May.
Article in English | MEDLINE | ID: mdl-25521093

ABSTRACT

BACKGROUND: Alternative splicing of the vascular endothelial growth factor (VEGF) gene results in a family of antiangiogenic isoforms (VEGFxxx b), not yet investigated in squamous cell carcinoma of the head and neck (SCCHN). We examined, therefore, the prognostic value of the relative expression of VEGF isoforms in SCCHN. METHODS: A tissue microarray comprising 187 SCCHNs was studied by immunohistochemistry with total VEGF (panVEGF) and VEGFxxx b-specific antibodies, and scored by 2 assessors for intensity and proportion. Scores were combined and expression ratios calculated. RESULTS: No meaningful significant differences were observed between panVEGF, VEGFxxx b, or expression ratio, and presence of lymphatic metastasis, or overall survival. This held true when tumor subsites were analyzed independently and when human papillomavirus (HPV) was accounted for in the oropharyngeal subgroup. CONCLUSION: Differential VEGF isoform expression is not a reliable prognostic biomarker for either the clinically node negative/pathologically node-positive neck or overall survival in pharyngeal and laryngeal SCCHNs.


Subject(s)
Carcinoma, Squamous Cell/metabolism , Head and Neck Neoplasms/metabolism , Vascular Endothelial Growth Factor A/metabolism , Adult , Aged , Aged, 80 and over , Alternative Splicing , Humans , Immunohistochemistry , Lymphatic Metastasis , Middle Aged , Prognosis , Protein Isoforms/metabolism , Squamous Cell Carcinoma of Head and Neck , Survival Rate , Tissue Array Analysis
2.
Carcinogenesis ; 36(6): 648-55, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25896444

ABSTRACT

Head and neck squamous cell carcinomas (HNSCC) are treated with surgery, radiotherapy and cisplatin-based chemotherapy, but survival from locally-advanced disease remains poor, particularly in patients whose tumors are negative for Human papillomavirus (HPV). Type 1 IGF receptor (IGF-1R) is known to promote tumorigenesis and resistance to cancer therapeutics. Here, we assessed IGF-1R immunohistochemistry on tissue microarrays containing 852 cores from 346 HNSCC patients with primary tumors in the oropharynx (n = 231), larynx (85), hypopharynx (28), oral cavity (2). Of these, 236 (68%) were HPV-negative, 110 (32%) positive. IGF-1R was detected in the cell membrane of 36% and cytoplasm of 92% of HNSCCs; in 64 cases with matched normal tonsillar epithelium, IGF-1R was overexpressed in the HNSCCs (P < 0.001). Overall survival (OS) and disease-specific survival (DSS) were reduced in patients whose tumors contained high membrane IGF-1R [OS: hazard ratio (HR) = 1.63, P = 0.006; DSS: HR = 1.63, P = 0.016], cytoplasmic IGF-1R (OS: HR = 1.58, P = 0.009; DSS: HR = 1.58, P = 0.024) and total IGF-1R (OS: HR = 2.02, P < 0.001; DSS: HR = 2.2, P < 0.001). High tumor IGF-1R showed significant association with high-tumor T-stage (P < 0.001) and HPV-negativity (P < 0.001), and was associated with shorter OS when considering patients with HPV-positive (P = 0.01) and negative (P = 0.006) tumors separately. IGF-1R was independently associated with survival in multivariate analysis including HPV, but not when lymphovascular invasion, perineural spread and T-stage were included. Of these factors, only IGF-1R can be manipulated; the association of IGF-1R with aggressive disease supports experimental incorporation of anti-IGF-1R agents into multimodality treatment programs for HPV-negative and high IGF-1R HPV-positive HNSCC.


Subject(s)
Carcinoma, Squamous Cell/mortality , Head and Neck Neoplasms/mortality , Papillomavirus Infections/complications , Receptor, IGF Type 1/biosynthesis , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/virology , Cell Transformation, Neoplastic/genetics , Combined Modality Therapy , Disease-Free Survival , Drug Resistance, Neoplasm/genetics , Female , Head and Neck Neoplasms/genetics , Head and Neck Neoplasms/virology , Humans , Male , Middle Aged , Neoplasm Staging , Papillomaviridae , Squamous Cell Carcinoma of Head and Neck , Young Adult
3.
Laryngoscope ; 124(12): 2739-44, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25042603

ABSTRACT

OBJECTIVES/HYPOTHESIS: The incidence of human papillomavirus (HPV)-driven disease beyond the oropharynx varies greatly in the reported literature. STUDY DESIGN: Case series. METHODS: Two hundred twenty-one samples were strictly classified to the subsites of oral cavity, larynx, or hypopharynx at the time of primary surgery. Formalin-fixed paraffin-embedded samples were subjected to a validated, tiered, diagnostic algorithm of p16 immunohistochemistry, high-risk HPV in situ hybridization, and quantitative polymerase chain reaction for HPV E6 DNA. An additional 60 oropharyngeal cases acted as an internal biological control. RESULTS: An incidence of 4% of HPV-driven cases was observed across the subsites outside the oropharynx compared to 70% of tumors confined within it. CONCLUSIONS: This is the first reporting of a broad range of nonoropharyngeal HPV rates using this validated diagnostic algorithm. It remains unclear whether patients with HPV-driven disease originating outside the oropharynx enjoy the same survival advantage apparent in those patients with oropharyngeal squamous cell carcinomas. LEVEL OF EVIDENCE: 4 Laryngoscope, 124:2739-2744, 2014.


Subject(s)
Carcinoma, Squamous Cell/diagnosis , Head and Neck Neoplasms/diagnosis , Papillomaviridae/genetics , Papillomavirus Infections/diagnosis , Biomarkers, Tumor/analysis , DNA, Viral/analysis , Diagnosis, Differential , Female , Follow-Up Studies , Humans , Immunohistochemistry , In Situ Hybridization , Male , Middle Aged , Oropharynx , Papillomaviridae/isolation & purification , Papillomavirus Infections/virology , Polymerase Chain Reaction , Real-Time Polymerase Chain Reaction , Retrospective Studies , Squamous Cell Carcinoma of Head and Neck
4.
Otolaryngol Head Neck Surg ; 144(1): 29-35, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21493383

ABSTRACT

OBJECTIVE: Head and neck squamous cell carcinoma (HNSCC) patients with N3 neck disease at presentation are the minority. Prognosis for such patients is poor, but there is disagreement about which treatment policy is best adopted. The aim of this study was to identify which groups of patients are best offered radical treatment, examining factors of association, prognosis, and survival. STUDY DESIGN: Prospective cohort study. SETTING: Regional tertiary head and neck cancer unit. SUBJECTS AND METHODS: Data were collected prospectively from patients treated for HNSCC with N3 nodal disease between 1975 and 2005. The data collected included age, sex, tumor TNM stage, histological grade, treatment, and survival. Odds ratio was used to calculate whether each parameter was statistically significant. Tumor-specific and observed survival curves were also calculated. RESULTS: A total of 275 patients had N3 disease. Multivariate analysis confirmed that advanced disease at the primary site (odds ratio = 4.6, P = .0261) mitigated against curative treatment. Comparison of tumor-specific survival between curative and palliative treatment strategies suggests that aggressive treatment is associated with greatly improved survival (median survival = 1.45 years, 95% confidence interval [CI] = 1.23-1.67 years; 5-year survival = 26.6%, CI = 17.14%-36.06%) compared with those treated palliatively (median survival = 3.18 months, CI = 3.06-3.30 months; no 5-year survivors; P < .0001). CONCLUSION: A major factor in determining treatment strategies for N3 disease HNSCC is the extent of disease at the primary site. These data suggest that aggressive treatment of the neck improves survival and should be considered in these patients.


Subject(s)
Carcinoma, Squamous Cell , Head and Neck Neoplasms , Carcinoma/mortality , Carcinoma/secondary , Carcinoma/therapy , Combined Modality Therapy , Follow-Up Studies , Head and Neck Neoplasms/mortality , Head and Neck Neoplasms/secondary , Head and Neck Neoplasms/therapy , Humans , Lymphatic Metastasis , Neoplasm Staging , Neoplasms, Squamous Cell/mortality , Neoplasms, Squamous Cell/secondary , Neoplasms, Squamous Cell/therapy , Prospective Studies , Squamous Cell Carcinoma of Head and Neck , Survival Rate/trends , Time Factors , United Kingdom/epidemiology
5.
Auris Nasus Larynx ; 38(3): 381-6, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21277126

ABSTRACT

OBJECTIVES: To test the validity of the comparative audit tool of POSSUM (Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity) against a cohort of 92 consecutive laryngectomies at a major tertiary referral centre for head and neck cancer. The major outcome measurements were 30-day mortality rates, formation of a pharyngo-cutaneous fistula, and length of hospital stay. METHODS: By means of a prospective and retrospective case note analysis. RESULTS: No significant difference between the mean POSSUM morbidity scores of those patients who did, or did not develop a fistula, was found (p=0.535, 95% C.I. -4.36 to 8.33). No significant correlation was observed between POSSUM predicted morbidity and bed occupancy [r=0.137 (95% C.I. -0.070 to 0.334)]. The Portsmouth POSSUM equation for mortality however did accurately predict the mortality rate (observed to expected ratio of 1.05). CONCLUSION: The authors propose that whilst there are many similar factors linked to mortality between cohorts of general surgical and head and neck patients, there are several highly specific risk factors in open surgery of the upper aero-digestive tract in the head and neck which are linked with wound breakdown and morbidity which are omitted from the POSSUM scoring system. The authors warn against the use of this comparative audit tool in its current state for such surgical procedures and recommend the creation of a specific POSSUM for head and neck cancer surgery.


Subject(s)
Laryngeal Neoplasms/mortality , Laryngeal Neoplasms/surgery , Laryngectomy/mortality , Postoperative Complications/mortality , Risk Assessment/statistics & numerical data , Severity of Illness Index , Adult , Aged , Aged, 80 and over , Cutaneous Fistula/mortality , England , Female , Fistula/mortality , Humans , Length of Stay/statistics & numerical data , Male , Medical Audit/statistics & numerical data , Middle Aged , Pharyngeal Diseases/mortality , Pharynx/surgery , Prospective Studies , Retrospective Studies , Survival Analysis
6.
Eur Arch Otorhinolaryngol ; 263(12): 1061-4, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17004088

ABSTRACT

Intratympanic membrane cholesteatoma, occurring in the absence of trauma or surgery to the ear, is rare with less than 20 cases reported in the literature. We report a rare incidental finding of intratympanic membrane cholesteatoma in a 12-month-old girl and review the literature.


Subject(s)
Cholesteatoma, Middle Ear/diagnosis , Tympanic Membrane/pathology , Adolescent , Adult , Child , Child, Preschool , Cholesteatoma, Middle Ear/surgery , Female , Humans , Infant , Male , Otoscopy , Tympanic Membrane/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...